Akebia Therapeutics Inc.

0.3986-0.0171-4.11%Vol 3.16M1Y Perf -83.82%
Aug 11th, 2022 16:00 DELAYED
BID0.3951 ASK0.4050
Open0.4150 Previous Close0.4157
Pre-Market- After-Market0.40
 - -  0.00 -0.88%
Target Price
1.75 
Analyst Rating
Hold 3.00
Potential %
339.04 
Finscreener Ranking
     30.35
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     32.06
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
     26.14
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
3.23 
Earnings Rating
Strong Sell
Market Cap73.28M 
Earnings Date
4th Aug 2022
Alpha-0.04 Standard Deviation0.24
Beta1.47 

Today's Price Range

0.39510.4199

52W Range

0.30003.35

5 Year PE Ratio Range

-3.00-1.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.91%
1 Month
-11.38%
3 Months
-3.44%
6 Months
-77.48%
1 Year
-83.82%
3 Years
-90.92%
5 Years
-97.21%
10 Years
-

TickerPriceChg.Chg.%
AKBA0.3986-0.0171-4.11
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
32.70
-115.70
-98.70
-92.00
-83.74
RevenueValueIndustryS&P 500US Markets
170.06M
0.93
-5.99
34.66
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.310.23174.19
Q01 2022-0.27-0.35-29.63
Q04 2021-0.33-0.40-21.21
Q03 2021-0.32-0.34-6.25
Q02 2021-0.30-0.51-70.00
Q01 2021-0.33-0.45-36.36
Q04 2020-0.43-0.60-39.53
Q03 2020-0.23-0.42-82.61
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.29-70.59Negative
9/2022 QR-0.17-6.25Negative
12/2022 FY-0.88-33.33Negative
12/2023 FY-0.348.11Positive
Next Report Date-
Estimated EPS Next Report-0.29
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume3.16M
Shares Outstanding183.85K
Shares Float181.56M
Trades Count5.86K
Dollar Volume1.28M
Avg. Volume6.72M
Avg. Weekly Volume5.96M
Avg. Monthly Volume4.37M
Avg. Quarterly Volume9.84M

Akebia Therapeutics Inc. (NASDAQ: AKBA) stock closed at 0.3986 per share at the end of the most recent trading day (a -4.11% change compared to the prior day closing price) with a volume of 3.16M shares and market capitalization of 73.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 360 people. Akebia Therapeutics Inc. CEO is John P. Butler.

The one-year performance of Akebia Therapeutics Inc. stock is -83.82%, while year-to-date (YTD) performance is -82.36%. AKBA stock has a five-year performance of -97.21%. Its 52-week range is between 0.3 and 3.35, which gives AKBA stock a 52-week price range ratio of 3.23%

Akebia Therapeutics Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 2.96, a price-to-sale (PS) ratio of 0.43, a price to cashflow ratio of 10.50, a PEG ratio of 2.32, a ROA of -48.84%, a ROC of -110.18% and a ROE of -241.73%. The company’s profit margin is -83.74%, its EBITDA margin is -98.70%, and its revenue ttm is $170.06 Million , which makes it $0.93 revenue per share.

Of the last four earnings reports from Akebia Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.29 for the next earnings report. Akebia Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Akebia Therapeutics Inc. is Hold (3), with a target price of $1.75, which is +339.04% compared to the current price. The earnings rating for Akebia Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Akebia Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Akebia Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.00, ATR14 : 0.04, CCI20 : -15.37, Chaikin Money Flow : -0.07, MACD : 0.00, Money Flow Index : 41.57, ROC : -1.58, RSI : 39.32, STOCH (14,3) : 52.18, STOCH RSI : 0.60, UO : 54.30, Williams %R : -47.82), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Akebia Therapeutics Inc. in the last 12-months were: David A. Spellman (Sold 8 203 shares of value $17 689 ), Dell Faulkingham (Sold 13 184 shares of value $28 515 ), John P. Butler (Sold 79 026 shares of value $171 143 ), Michel Dahan (Sold 14 660 shares of value $31 718 ), Nicole R. Hadas (Sold 21 062 shares of value $45 615 ), Steven C. Gilman (Sold 4 567 shares of value $1 653 ), Steven Keith Burke (Sold 16 098 shares of value $35 513 ), Violetta Cotreau (Sold 9 779 shares of value $21 838 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (100.00 %)
5 (83.33 %)
6 (85.71 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
1 (16.67 %)
1 (14.29 %)
Summary RatingHold
3.00
Hold
3.33
Hold
3.29

Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

CEO: John P. Butler

Telephone: +1 617 871-2098

Address: 245 First Street, Cambridge 02142, MA, US

Number of employees: 360

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

69%31%

Bearish Bullish

73%27%

Bearish Bullish

69%31%

TipRanks News for AKBA

Mon, 16 May 2022 11:26 GMT Akebia Therapeutics (AKBA) Receives a Hold from Mizuho Securities

- TipRanks. All rights reserved.

Mon, 16 May 2022 10:28 GMT Akebia Therapeutics (AKBA) Gets a Hold Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Tue, 10 May 2022 16:05 GMT Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (AKBA) and Cerevel Therapeutics Holdings (CERE)

- TipRanks. All rights reserved.

Tue, 10 May 2022 02:15 GMT Akebia Therapeutics (AKBA) Gets a Hold Rating from Mizuho Securities

- TipRanks. All rights reserved.

Mon, 11 Apr 2022 12:13 GMT Why Was Akebia Trading Lower in Pre-Market Session

- TipRanks. All rights reserved.

Thu, 07 Apr 2022 15:05 GMT Akebia Therapeutics (AKBA) Gets a Hold Rating from Needham

- TipRanks. All rights reserved.

Thu, 31 Mar 2022 11:35 GMT Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (AKBA) and TFF Pharmaceuticals (TFFP)

- TipRanks. All rights reserved.

Thu, 31 Mar 2022 00:25 GMT Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (AKBA) and Brainstorm Cell Therapeutics (BCLI)

- TipRanks. All rights reserved.

Mon, 21 Mar 2022 09:05 GMT Analysts Offer Insights on Healthcare Companies: and Akebia Therapeutics (AKBA)

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 04:45 GMT Akebia Therapeutics (AKBA) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits